Biocryst Pharmaceuticals (BCRX) Cost of Revenue (2012 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Cost of Revenue came in at $5.4 million in Q1 2026, up 17.71% YoY from $4.6 million in Q1 2025, and down 43.53% on a QoQ basis from $9.5 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Cost of Revenue (2012 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 15 years of Cost of Revenue data on file, last reported at $5.4 million in Q1 2026.
- Quarterly Cost of Revenue rose 17.71% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.9 million (up 27.69% YoY) and the FY2025 annual result came in at $19.1 million, up 55.47% from the prior year.
- Cost of Revenue retreated to $5.4 million in Q1 2026, from $9.5 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $9.5 million in Q4 2025 to a low of $236000.0 in Q1 2022.
- A 5-year average of $2.8 million and a median of $2.2 million in 2025 frame the typical range for Cost of Revenue.
- The widest YoY moves for Cost of Revenue: up 499.49% in 2022, down 96.02% in 2022.
- Tracing BCRX's Cost of Revenue over 5 years: stood at $2.4 million in 2022, then sank by 34.66% to $1.6 million in 2023, then soared by 291.39% to $6.1 million in 2024, then soared by 56.25% to $9.5 million in 2025, then tumbled by 43.53% to $5.4 million in 2026.
- The last three Cost of Revenue figures came in at $5.4 million (Q1 2026), $9.5 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.45 Bn | 2.10 Bn | 214.41 Mn | 3.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.84 Mn |
| Jun 30, 2026 | 3.84 Mn |
| Mar 31, 2026 | 5.38 Mn |
| Mar 31, 2026 | 5.38 Mn |
| Dec 31, 2025 | 9.52 Mn |
| Dec 31, 2025 | 9.52 Mn |
| Sep 30, 2025 | 2.19 Mn |
| Sep 30, 2025 | 2.19 Mn |
| Jun 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 2.80 Mn |
| Mar 31, 2025 | 4.57 Mn |
| Mar 31, 2025 | 4.57 Mn |
| Dec 31, 2024 | 6.09 Mn |
| Dec 31, 2024 | 6.09 Mn |
| Sep 30, 2024 | 3.21 Mn |
| Sep 30, 2024 | 3.21 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.27 Mn |